Sinobiopharma, Inc. (OTCBB:SNBP) ("Sinobiopharma") is pleased to announce that the Company received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material (Certificate #2009S01805) from the Chinese State Food and Drug Administration ("SFDA").
Get Rich Penny Stocks is a leading financial publication that is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotininThe Company is now awaiting GMP certification to manufacture Gabexate mesylate.Sinobiopharma Inc. is an emerging, fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anaesthesia-assisted agents and cardiovascular drugs. Founded in 2004, Sinobiopharma employs more than 80 people at its corporate office and production facility in Nantong, China.Sinobiopharma's new Chinese patented formulation of Cisatracurium Besylate is the world's first that can be stored at room temperature. It also costs a fraction of global giant GSK's version of the drug, Nimbex, which goes off patent in the U.S. in 2010.
Sign up for the Free GetRichPennyStocks Newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
GetRichPennyStocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that could be on the brink of a breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
